Amid rising global scrutiny of the wider medical cannabis prescription model, and with markets like France leaning into pharmaceutical-grade regulation, the pharma cannabis sector is shaping up to be one of the most dynamic and closely watched corners of the industry.
Australia’s medical cannabis market is thriving, with revenues expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028, according to Prohibition Partners’ Global Cannabis Report: 5th Edition.
The shock announcement this week that a federal trade court had ruled that key elements of President Trump’s flagship tariff
Israel has seemingly followed in the footsteps of its US ally this week after announcing plans to impose 165% tariffs on cannabis imports from Canada.
Licensed cannabis operators and ancillary companies are bracing for rising business costs, lost customers and vendor backlash in the wake of President Donald Trump’s erratic blanket tariffs that have rattled the global economy and stoked fears of a recession and accelerated inflation in the United States.
Argent BioPharma [stock_market_widget type=”chart” template=”line” assets=”RGT.AX” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Argent BioPharma has
Tilray’s stock price has tumbled some 24% since the start of the week as its Q3 2025 financial figures failed
The incomprehensible economic strategy of President Trump’s global tariffs has left almost every US industry scratching their heads, and fearing
‘Liberation day’, set to take place on April 02, has been pitched as the day the Trump administration will roll out sweeping and aggressive tariffs for all of the US’ trading partners.
We won’t spam you
